本文選題：子宮內(nèi)膜癌 + microRNA　； 參考：《廣西醫(yī)科大學(xué)》2015年博士論文

【摘要】：子宮內(nèi)膜癌(endometrial carcinoma, EC)是最常見的婦科惡性腫瘤之一,嚴(yán)重威脅婦女健康。近年由于環(huán)境、平均壽命延長、激素替代療法應(yīng)用等各種因素的影響,其發(fā)病率逐年上升。美國癌癥協(xié)會(huì)統(tǒng)計(jì)在2012年全球大概有47130例新發(fā)子宮內(nèi)膜癌患者,已經(jīng)躍居發(fā)達(dá)國家女性生殖道惡性腫瘤首位。盡管目前對(duì)子宮內(nèi)膜癌的治療方法和技術(shù)不斷發(fā)展,但對(duì)晚期和復(fù)發(fā)的子宮內(nèi)膜癌的治療仍為棘手。進(jìn)一步研究和尋找子宮內(nèi)膜癌的新的治療手段尤為重要。國內(nèi)外研究證實(shí)腫瘤發(fā)生發(fā)展是一個(gè)復(fù)雜的分子調(diào)控失控過程,與抑癌基失活、癌基因的激活從而導(dǎo)致細(xì)胞生長失控,細(xì)胞基質(zhì)間黏附及細(xì)胞信號(hào)傳導(dǎo)異常密切聯(lián)系。因此,探索子宮內(nèi)膜癌發(fā)生的分子學(xué)基礎(chǔ),尋找安全可靠的切入點(diǎn)抑制子宮內(nèi)膜癌細(xì)胞生長,轉(zhuǎn)移,對(duì)預(yù)防子宮內(nèi)膜癌的發(fā)生和改善子宮內(nèi)膜癌患者的預(yù)后,保護(hù)我國婦女健康具有重大意義。MicroRNA(miRN A)是近年來發(fā)現(xiàn)的一類保守的長度為19～24個(gè)堿基的非編碼RNA分子,廣泛存在真核生物體內(nèi),其通過與靶基因mRNA3’非翻譯區(qū)(3’UTR)相對(duì)應(yīng)的靶序列完全或不完全的互補(bǔ)結(jié)合,抑制或促進(jìn)mRNA降解,調(diào)節(jié)基因,這些僅占人類基因1%的miRNA分子,卻調(diào)控著人類三分之一以上基因的表達(dá)、修飾、轉(zhuǎn)錄和翻譯的過程,對(duì)細(xì)胞增殖、分化及凋亡等生物學(xué)功能起著重要的調(diào)控作用。miRNA是腫瘤研究領(lǐng)域中的熱點(diǎn),其包括miRNA表達(dá)譜篩選,分子結(jié)構(gòu),調(diào)控機(jī)制,靶基因預(yù)測(cè)等研究。越來越多的研究證實(shí),niRNA在多種惡性腫瘤中存在表達(dá)異常,在腫瘤中高表達(dá)的niRNA可能發(fā)揮癌基因的作用,而低表達(dá)的miRNA發(fā)揮抑癌基因作用。miRNA的發(fā)現(xiàn)可能成為極有應(yīng)用價(jià)值的分子標(biāo)志物,為惡性腫瘤的早期診斷和預(yù)后評(píng)估提供新方向。miR-944是目前學(xué)者關(guān)注的新焦點(diǎn),目前國內(nèi)外對(duì)關(guān)于miR-944功能的報(bào)道還比較少,初步研究發(fā)現(xiàn)：miR-944在子宮內(nèi)膜癌、宮頸癌及胰腺癌等惡性腫瘤中表達(dá)顯著增高,我們推測(cè)其在腫瘤中發(fā)揮癌基因的作用。但迄今為止,對(duì)子宮內(nèi)膜癌組織進(jìn)行差異表達(dá)miRNA的篩選及分析研究甚少。本課題旨在闡明子宮內(nèi)膜癌組織中的miRNA表達(dá)譜及miR-944對(duì)子宮內(nèi)膜癌生物學(xué)行為影響及調(diào)控作用的機(jī)制研究。研究?jī)?nèi)容包括以下四部分：第一部分 子宮內(nèi)膜癌組織中差異表達(dá)miRNA的篩選研究目的：篩選出子宮內(nèi)膜癌組織中的差異表達(dá)的miRNA分子,獲得子宮內(nèi)膜癌miRNA表達(dá)譜,尋找新的診斷標(biāo)志物。方法：收集3例子宮內(nèi)膜癌患者的癌變內(nèi)膜組織和3例正常對(duì)照組子宮內(nèi)膜組織,提取RNA,應(yīng)用丹麥Exiqon公司的miRCURYTM LNA miRNA芯片,篩選出子宮內(nèi)膜癌組織中的差異表達(dá)的miRNA分子,采用實(shí)時(shí)定量逆轉(zhuǎn)錄聚合酶鏈反應(yīng)(qRT-PCR)在樣本中進(jìn)行驗(yàn)證。結(jié)果：1.3例癌組織和3例正常內(nèi)膜組織的總RNA抽取及質(zhì)檢,結(jié)果顯示,所提取的總RNA的電泳可見帶28S和18s條帶,260／A280的值都介于1.8-2.1之間,檢測(cè)RNA檢測(cè)結(jié)果符合雜交芯片實(shí)驗(yàn)要求。2. miRNA芯片結(jié)果顯示：子宮內(nèi)膜癌組織與正常子宮內(nèi)膜組織存在有顯著差異表達(dá)的miRNA:有14個(gè)miRNA表達(dá)上調(diào),6個(gè)miRNA表達(dá)下調(diào)。3.采用qRT-PCR方法對(duì)上調(diào)的miR-944、miR-373及下調(diào)的miR-548、miR-885進(jìn)行驗(yàn)證,結(jié)果顯示：子宮內(nèi)膜癌中miR-944、miR-373上調(diào)的倍數(shù)為3.13倍和4.2倍,1niR-548、miR-885下調(diào)倍數(shù)為2.08倍及3.84倍,與芯片結(jié)果比較,趨勢(shì)一致。結(jié)論miRNA表達(dá)譜芯片可用于分析子宮內(nèi)膜癌組織miRNA表達(dá)譜；通過miRCURYTMLNA miRNA芯片篩選結(jié)合qRT-PCR驗(yàn)證,共得到14個(gè)顯著上調(diào)6個(gè)顯著下調(diào)的miRNA,為下一步開展子宮內(nèi)膜癌組織niRNA的研究及功能學(xué)研究提供實(shí)驗(yàn)基礎(chǔ)。第二部分 子宮內(nèi)膜癌組織中miR-944表達(dá)及其與臨床病理特征的關(guān)系目的：探討miR-944在子宮內(nèi)膜癌組織中的表達(dá),并分析其與臨床病理特征的關(guān)系。方法：收集2012年3月—2014年4月在廣西醫(yī)科大學(xué)第一附屬醫(yī)院進(jìn)行手術(shù)治療的子宮內(nèi)膜癌患者的癌變內(nèi)膜組織40例,收集同期因子宮肌瘤等良性病變行子宮切除術(shù)的正常子宮內(nèi)膜組織25例作為對(duì)照。采用qRT-PC R方法進(jìn)行miR-944表達(dá)水平的相對(duì)定量檢測(cè),并分析其與患者臨床病理特征的關(guān)系。結(jié)果：1.miR-944在子宮內(nèi)膜癌組織及正常子宮內(nèi)膜組織中的表達(dá)子宮內(nèi)膜癌組miR-944的表達(dá)水平高于及正常內(nèi)膜組(P0.05)。2.miR-944與臨床病理特征的關(guān)系miRNA-944的表達(dá)與組織學(xué)分級(jí)、病理類型、淋巴轉(zhuǎn)移、肌層浸潤深度及FIGO分期因素相關(guān),均有統(tǒng)計(jì)學(xué)意義(P0.05),與年齡無相關(guān)性。結(jié)論：miR-944在子宮內(nèi)膜癌組織中高表達(dá),提示miR-944可能參與子宮內(nèi)膜癌發(fā)生及發(fā)展；miR-944的表達(dá)與組織學(xué)分級(jí)、病理類型、淋巴轉(zhuǎn)移、肌層浸潤深度及FIGO分期因素相關(guān),可能可以預(yù)測(cè)子宮內(nèi)膜癌的惡性程度及不良預(yù)后。第三部分 miR-944對(duì)子宮內(nèi)膜癌細(xì)胞生物學(xué)行為的影響目的：探討miR-944對(duì)子宮內(nèi)膜癌Ishikawa細(xì)胞和KLE細(xì)胞生物學(xué)行為的影響。方法：人工合成miR-944的模擬物mimics及抑制物inhibitor,利用陽離子脂質(zhì)體法,分別轉(zhuǎn)染至人子宮內(nèi)膜癌Ishikawa細(xì)胞和KLE細(xì)胞中。設(shè)置陰性對(duì)照組及空白對(duì)照組。采用Cell Counting Kit-8(CCK-8)法對(duì)比轉(zhuǎn)染前后細(xì)胞增殖生長能力的區(qū)別；流式細(xì)胞學(xué)對(duì)比轉(zhuǎn)染前后細(xì)胞凋亡情況的區(qū)別；Transwell小室法對(duì)比轉(zhuǎn)染前后細(xì)胞遷移和侵襲能力的區(qū)別。結(jié)果：1.細(xì)胞轉(zhuǎn)染效果熒光倒置顯微鏡觀察轉(zhuǎn)染后的miR-944 mimics的轉(zhuǎn)染效率,通過熒光鏡下視野與光鏡下視野對(duì)比,Ishikawa細(xì)胞和KEL細(xì)胞的轉(zhuǎn)染效率大約為85%。2. miR-944-mimics及miR-944-inhibitor(?)子宮內(nèi)膜癌Ishikawa細(xì)胞KLE細(xì)胞生物學(xué)行為的影響。(1)CCK8法檢測(cè)細(xì)胞增殖實(shí)驗(yàn)分別在(24h、48h、72h、96h)四個(gè)時(shí)間點(diǎn)行CCK8檢測(cè)Ishikawa和KLE細(xì)胞的OD值,結(jié)果顯示,相對(duì)于對(duì)照組細(xì)胞,轉(zhuǎn)染了miR-944mimics的Ishikawa細(xì)胞和KLE細(xì)胞增殖活性均增強(qiáng),轉(zhuǎn)染了niR-944inhibitor的Ishikawa細(xì)胞和KLE細(xì)胞增殖活性均降低(P0.05)。(2)流式細(xì)胞術(shù)檢測(cè)細(xì)胞凋亡對(duì)miR-944轉(zhuǎn)染48h后的Ishikawa細(xì)胞進(jìn)行流式細(xì)胞術(shù)細(xì)胞凋亡分析,結(jié)果顯示,B組、NC組、miR-944inhibitor組和miR-944mimics組凋亡率分別為0.58±0.06%、0.66±0.07%、11.74±0.19%、0.68±0.03%, miR-944inhibitor組凋亡率明顯高于B組(P0.05),niR-944mimics組凋亡率與B組差別無統(tǒng)計(jì)學(xué)意義(P0.05)。對(duì)miR-944轉(zhuǎn)染48h后的KLE細(xì)胞進(jìn)行流式細(xì)胞術(shù)細(xì)胞凋亡分析,結(jié)果顯示,B組、NC組、miR-944 inhibitor組和miR-944mimics組凋亡率分別為2.55±0.23%、2.53±0.10%、5.13±0.14%、2.99±0.18%,miR-944inhibitor凋亡率明顯高于B組(P0.05),miR-944mimics組凋亡率與B組差別無統(tǒng)計(jì)學(xué)意義(P0.05)。(3)細(xì)胞侵襲實(shí)驗(yàn)檢測(cè)轉(zhuǎn)染48h后各組KLE細(xì)胞遷移能力,對(duì)穿膜細(xì)胞進(jìn)行拍照和計(jì)數(shù),結(jié)果顯示,轉(zhuǎn)染miR-944 mimics的KLE細(xì)胞穿膜數(shù)量較B組明顯增多(P0.05)；轉(zhuǎn)染miR-944 inhibitor的KLE細(xì)胞穿膜數(shù)量較B組明顯減少(P0.05)。Ishikawa細(xì)胞過膜后鋪展性不好,拍照后無法計(jì)數(shù),CCK8方法檢測(cè)過膜細(xì)胞,結(jié)果顯示：相對(duì)于對(duì)照組細(xì)胞,轉(zhuǎn)染了miR-944 mimics的 Ishikawa細(xì)胞OD值高,間接反映了mimics組的穿膜數(shù)量多；轉(zhuǎn)染miR-944 inhibitor 的 Ishikawa細(xì)胞OD低,間接反映了inhibitor組的穿膜數(shù)量少(P0.05)。結(jié)論：miR-944可促進(jìn)子宮內(nèi)膜癌細(xì)胞的增殖,侵襲與轉(zhuǎn)移能力,降低miR-944水平可促進(jìn)細(xì)胞凋亡,表明miR-944可能發(fā)揮癌基因的作用參與子宮內(nèi)膜癌的發(fā)生發(fā)展。第四部分 miR-944對(duì)子宮內(nèi)膜癌細(xì)胞生物學(xué)行為調(diào)控的靶基因預(yù)測(cè)及鑒定目的：預(yù)測(cè)并實(shí)驗(yàn)證實(shí)miR-944的靶基因,初步探討miR-944的生物學(xué)機(jī)制。方法：登陸1nicroRN A庫及靶基因預(yù)測(cè)的網(wǎng)站,在線檢測(cè)或下載靶基因預(yù)測(cè)軟件,綜合運(yùn)用TargetScan(http://genes.mit.edu/targetscan)、Mirbase (http://mirbase.org)、miRanda (http://www.microrna.org)生物信息篩選miR-944最可能的靶基因。Western blot (WB)對(duì)比轉(zhuǎn)染前后細(xì)胞表達(dá)靶基因的區(qū)別。構(gòu)建最可能的靶基因的3’UTR雙熒光素酶報(bào)告載體,檢測(cè)熒光素的活性以期在基因水平上驗(yàn)證靶基因上存在miR-944的作用靶點(diǎn)。結(jié)果：1. 預(yù)測(cè)miR-944的靶基因通過預(yù)測(cè)軟件miRanda、Mirbase及TargetScan預(yù)測(cè)miR-944的靶基因,三個(gè)軟件交集的niRNA-944靶基因共70個(gè)；登陸基因庫,查詢以上靶基因功能,尤其注意與惡性腫瘤侵襲轉(zhuǎn)移密切相關(guān)的功能基因。最后選擇非受體型蛋白酪氨酸磷酸酶14(protein tyrosine phosphatase non-receptor type 14,PTPN14)作為miR-944的可能靶基因來進(jìn)一步研究。應(yīng)用Targetscan預(yù)測(cè)miR-944與PTPN14基因的結(jié)合位點(diǎn)。2.蛋白水平驗(yàn)證PTPN14是否為miR-944的靶基因miR-944mimics組的KLE細(xì)胞的PTPN14蛋白表達(dá)量與B組比較下降,差異有統(tǒng)計(jì)學(xué)意義(P0.05)；niR-944inhibitor組則高于B組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)表明miR-944模擬物能降低KLE細(xì)胞中PTPN14蛋白的表達(dá),B組與NC組比較無統(tǒng)計(jì)學(xué)意義。在Ishikawa細(xì)胞中,miR-944mimics組,miR-944 inhibitor組的PTPN14蛋白表達(dá)量與B組均無差異(P0.05)。3. miR-944與PTPN14的結(jié)合結(jié)合靶點(diǎn)驗(yàn)證將niR-944mimics與連接了PTPN14基因3'-UTR區(qū)的pmirGLO載體共轉(zhuǎn)染KLE細(xì)胞,實(shí)驗(yàn)設(shè)立陽性對(duì)照組及陰性對(duì)照組,重組報(bào)告質(zhì)粒的熒光素酶活性,結(jié)果顯示與對(duì)照組比較,實(shí)驗(yàn)組的熒光素酶活性顯著下調(diào),差別有統(tǒng)計(jì)學(xué)意義(P0.05)結(jié)論：PTPN14是miR-944是其中一個(gè)靶基因,抑制PTPN14的表達(dá),可能是miR-944促進(jìn)子宮內(nèi)膜癌細(xì)胞增殖及侵襲轉(zhuǎn)移的作用機(jī)制之一。
[Abstract]:Endometrial carcinoma (EC) is one of the most common gynecologic malignancies. It is a serious threat to women's health. In recent years, the incidence of the cancer is increasing year by year because of the influence of environment, prolonged life expectancy, and hormone replacement therapy. The American Cancer Association combined with 47130 new endometrium cancers worldwide in 2012. Patients have been in the first place in women's reproductive tract cancer in developed countries. Although the treatment and techniques for endometrial cancer are developing continuously, the treatment of advanced and recurrent endometrial cancer is still difficult. Further research and search for new treatment hand Duan You for endometrial cancer are important. Domestic and foreign studies have confirmed the occurrence of tumor. Development is a complex process of uncontrolled molecular regulation, which is associated with the inactivation of tumor suppressor base, the activation of the oncogene and the close relationship between cell growth out of control, cell matrix adhesion and abnormal cell signal transduction. Shift, to prevent endometrial cancer and improve the prognosis of endometrial cancer patients, the protection of the health of women in China is of great significance.MicroRNA (miRN A) is a class of conserved non coded RNA molecules with 19~24 bases in length. There is a wide range of eukaryotes, and it passes through the target gene mRNA3 'non translation zone (3' UTR). A complete or incomplete combination of corresponding target sequences, inhibiting or promoting mRNA degradation and regulating genes, which only occupy 1% of the human gene miRNA, regulate the expression, modification, transcription and translation of more than 1/3 of the human genes, and play an important role in regulating biological functions such as cell proliferation, differentiation and apoptosis,.Mi RNA is a hot spot in the field of cancer research, which includes the screening of miRNA expression spectrum, molecular structure, regulation mechanism and target gene prediction. More and more studies have proved that niRNA has abnormal expression in a variety of malignant tumors, and the high expression of niRNA in the tumor may play the role of cancer based cause, and the low expression miRNA plays the role of tumor suppressor gene. The discovery of miRNA may be a highly valuable molecular marker, providing new direction for the early diagnosis and prognosis evaluation of malignant tumor..miR-944 is a new focus of attention at present. There are few reports about miR-944 function at home and abroad. The preliminary study found that miR-944 is in endometriosis, cervix and pancreatic cancer. There is a significant increase in the expression of the tumor in the tumor, we speculate that it plays the role of the oncogene in the tumor. But so far, the screening and analysis of differential expression of miRNA in endometrial carcinoma tissue is very few. The purpose of this study is to clarify the expression of miRNA in endometrial carcinoma and the effect of miR-944 on the biological behavior of endometrial carcinoma and its regulation and control. Research on the mechanism of action. The study includes the following four parts: the first part: the screening of differential expression of miRNA in endometrial carcinoma: screening the differentially expressed miRNA molecules in endometrial carcinoma, obtaining the miRNA expression profile of endometrial carcinoma and finding new diagnostic markers. Methods: 3 cases of endometrial carcinoma were collected. The endometrial tissue of the patients and the endometrium of 3 normal controls, RNA, and the miRCURYTM LNA miRNA chip of Danish Exiqon company were used to screen the differentially expressed miRNA molecules in endometrial carcinoma tissue, and the real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to verify the samples. Results: 1.3 cases of cancer tissue were found. The total RNA extraction and quality examination of 3 cases of normal endometrium showed that the extracted total RNA electrophoresis showed 28S and 18S bands, and the values of 260 / A280 were between 1.8-2.1. The detection results of RNA conformed to the requirements of the hybridization chip experiment. The results of.2. miRNA chip showed that there was a significant difference between endometrial carcinoma tissue and normal endometrium. The differential expression of miRNA: was up to 14 miRNA expressions, and 6 miRNA expression down-regulation.3. was verified by qRT-PCR method for up regulated miR-944, miR-373 and down regulated miR-548 and miR-885. The results showed that the multiplier of miR-944, miR-373 up-regulated in endometrial carcinoma was 3.13 times and 4.2 times, 1niR-548, 2.08 times and 3.84 times the down-regulation of 1niR-548. The results were the same. Conclusion the miRNA expression chip can be used to analyze the miRNA expression profile of endometrial carcinoma tissue. Through the miRCURYTMLNA miRNA chip screening and qRT-PCR verification, 14 significantly up regulation 6 down regulated miRNA are obtained, which can provide experimental basis for the next step in the study and functional study of endometrial carcinoma group niRNA. Second part of the expression of miR-944 in endometrial carcinoma and its relationship with the clinicopathological features: To explore the expression of miR-944 in endometrial carcinoma and to analyze its relationship with the clinicopathological features. Methods: to collect the uterus from March 2012 to April 2014 at the First Affiliated Hospital of Guangxi Medical University. 40 cases of endometrial carcinoma in endometrial carcinoma, 25 cases of normal endometrium with hysterectomy and hysterectomy were collected for the same period as control. The relative quantitative detection of miR-944 expression was carried out by qRT-PC R method, and the relationship with the patients' clinicopathological characteristics was analyzed. Results: 1.miR-944 was in endometrial carcinoma. The expression level of endometrial carcinoma group miR-944 in tissue and normal endometrium was higher than that of normal endometrium (P0.05).2.miR-944 and clinicopathological features. The expression of miRNA-944 was related to histological classification, pathological type, lymphatic metastasis, depth of myometrium infiltration and FIGO staging, and was statistically significant (P0.05). Conclusion: miR-944 is highly expressed in endometrial carcinoma, suggesting that miR-944 may be involved in the occurrence and development of endometrial carcinoma, and the expression of miR-944 is related to histological classification, pathological type, lymphatic metastasis, depth of myometrium infiltration and FIGO staging, which may predict the malignancy and poor prognosis of endometrial carcinoma. The effect of the three part of miR-944 on the biological behavior of endometrial carcinoma cells: To explore the effect of miR-944 on the biological behavior of endometrial carcinoma Ishikawa cells and KLE cells. Methods: artificial synthesis of miR-944 simulants, mimics and inhibitor inhibitor, were transfected to human endometrial carcinoma Ishikawa cells by cationic liposome method. And KLE cells. Set negative control group and blank control group. Cell Counting Kit-8 (CCK-8) method was used to compare the proliferation and growth ability of cells before and after transfection; flow cytology compared the difference of cell apoptosis before and after transfection; Transwell cell method compared the difference of cell migration and invasion before and after transfection. Results: 1. cells Transfection effect with fluorescence inverted microscope to observe transfection efficiency of miR-944 mimics after transfection, the transfection efficiency of Ishikawa cells and KEL cells is about 85%.2. miR-944-mimics and miR-944-inhibitor (?) Ishikawa cell KLE cell biological behavior of 85%.2. miR-944-mimics and miR-944-inhibitor (?) endometrial carcinoma. (1) CCK8 method CCK8 detection of Ishikawa and KLE cells at four time points (24h, 48h, 72h, 96h) detected the OD values of Ishikawa and KLE cells respectively. The results showed that the proliferation activity of Ishikawa cells and KLE cells transfected with miR-944mimics was enhanced compared with that of the control group, and both niR-944inhibitor Ishikawa cells and cell proliferation activities were reduced. (2) flow cytometry was used to detect apoptosis in Ishikawa cells transfected with 48h by flow cytometry. The apoptosis rate of B group, NC group, miR-944inhibitor group and miR-944mimics group was 0.58 + 0.06%, 0.66 + 0.07%, 11.74 + 0.19% and 0.68 + 0.03%, respectively. The apoptosis rate of miR-944inhibitor group was significantly higher than that of the B group (P0.05). There was no significant difference in apoptosis rate between group niR-944mimics and group B (P0.05). The apoptosis of KLE cells after miR-944 transfected with 48h showed that the apoptosis rate of B group, NC group, miR-944 inhibitor group and miR-944mimics group was 2.55 + 0.23%, 2.53 + 0.10%, 5.13 + 0.14%, 2.99 + 0.18%, and the apoptotic rate of miR-944inhibitor was obvious Higher than group B (P0.05), there was no significant difference in the apoptosis rate between group miR-944mimics and group B (P0.05). (3) cell invasion test was used to detect the migration ability of KLE cells in each group after transfection of 48h and to take pictures and count of membrane cells. The results showed that the number of membrane transfected on miR-944 mimics KLE cells was significantly higher than that of B group (P0.05). The number of LE cells was significantly less than that in the B group (P0.05), the spread of.Ishikawa cells was not good, and the number of membrane cells could not be counted after taking pictures. CCK8 method detected the membrane cells. The result showed that compared with the control group, the Ishikawa cells transfected with miR-944 mimics had high OD value, which indirectly reflected the number of membrane in the mimics group, and the transfection of miR-944 inhibitor. The Ishikawa cell OD is low, which indirectly reflects the small number of membrane in the inhibitor group (P0.05). Conclusion: miR-944 can promote the proliferation, invasion and metastasis of endometrial cancer cells, and reduce the level of miR-944 to promote cell apoptosis. It is suggested that miR-944 may play the role of oncogene in the development of endometrial carcinoma. The fourth part of miR-944 against the child. The target gene prediction and identification of the biological behavior regulation of endometrial carcinoma cells: predict and verify the target gene of miR-944 and preliminarily discuss the biological mechanism of miR-944. Methods: landing on the 1nicroRN A library and the site of target gene prediction, on-line detection or downloading target gene prediction soft parts, and using TargetScan (http://genes.mit.edu/ta) Rgetscan), Mirbase (http://mirbase.org), miRanda (http://www.microrna.org) biological information screening miR-944 the most likely target gene.Western blot (WB) to compare the difference between the target gene and the target gene before and after the transfection. The 3 'UTR double luciferase reporter vector of the most likely target gene is constructed to detect the activity of fluorescein at the gene level. The target genes of miR-944 were tested on the target gene. Results: 1. the target gene for predicting miR-944 was predicted by the software miRanda, Mirbase and TargetScan for the prediction of the target genes of miR-944, and 70 niRNA-944 target genes of the three software intersections; the landfall gene pool was used to query the function of the target gene, especially closely related to the invasion and metastasis of malignant tumor. Finally, we chose non receptor type protein tyrosine phosphatase 14 (protein tyrosine phosphatase non-receptor type 14, PTPN14) as a possible target gene for miR-944 to further study. Using Targetscan to predict the.2. protein of the binding site of miR-944 and PTPN14 genes to verify that PTPN14 is the target gene. The expression of PTPN14 protein in KLE cells in group imics was lower than that in group B (P0.05), and in group niR-944inhibitor, the difference was statistically significant (P0.05) showed that the miR-944 mimic could reduce the expression of PTPN14 protein in KLE cells, and there was no statistical significance in B group. In group miR-944, the expression of PTPN14 protein in group inhibitor was not different from that of B group (P0.05).3. miR-944 and PTPN14 binding target verifying that niR-944mimics was co transfected with pmirGLO carrier of 3'-UTR region of PTPN14 gene, and the experiment set up positive control group and negative control group. Compared with the control group, the luciferase activity of the experimental group was significantly reduced, and the difference was statistically significant (P0.05) conclusion: PTPN14 was one of the target genes, which inhibited the expression of PTPN14, which may be one of the mechanisms of miR-944 to promote the proliferation and invasion and metastasis of endometrial carcinoma cells.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2015
【分類號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳金明,李偉華,王家頓,馮永東,吳劍宏,龔建平;結(jié)腸癌細(xì)胞凋亡與增殖的平衡及其與預(yù)后的關(guān)系[J];癌癥;2005年05期

2 陳玉芬;;子宮內(nèi)膜癌患者血清中miR-155的表達(dá)及其臨床意義研究[J];中國醫(yī)藥導(dǎo)刊;2014年01期

3 薛紀(jì)森;張乾;李曉琳;胡燕;楊孝軍;顏笑健;鄭飛云;;子宮內(nèi)膜癌Ⅰ型和Ⅱ型miRNA表達(dá)譜差異的分析[J];實(shí)用醫(yī)學(xué)雜志;2011年22期

4 劉潛;付潔;宋海峰;;微小RNA分析技術(shù)研究進(jìn)展[J];生物技術(shù)通訊;2013年05期

5 何中慧;徐紅;牛菲菲;;脾酪氨酸激酶在子宮內(nèi)膜癌中的表達(dá)及意義[J];實(shí)用醫(yī)學(xué)雜志;2014年11期

6 劉立鵬;于瀟華;王曉春;郭小芳;田智;龍昱;粟敏;羅sベ，

本文編號(hào)：2059921